Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA) is a publicly traded Healthcare sector company. As of May 21, 2026, KNSA trades at $54.28 with a market cap of $4.13B and a P/E ratio of 54.96. KNSA moved +1.84% today. Year to date, KNSA is +32.20%; over the trailing twelve months it is +103.30%. Its 52-week range spans $17.82 to $59.87. Analyst consensus is strong buy with an average price target of $64.00. Rallies surfaces KNSA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kiniksa Launches DTC Campaign to Reach 40,000 Recurrent Pericarditis Patients: Kiniksa has launched Heart’s Home, a Direct-to-Consumer campaign for ARCALYST across connected TV, digital and social media to educate roughly 40,000 U.S. patients with recurrent pericarditis on treatment options. ARCALYST is the first FDA-approved IL-1 blocker for recurrent pericarditis, offering weekly subcutaneous dosing to prevent flare-ups.
| Metric | Value |
|---|---|
| Price | $54.28 |
| Market Cap | $4.13B |
| P/E Ratio | 54.96 |
| EPS | $0.98 |
| Dividend Yield | 0.00% |
| 52-Week High | $59.87 |
| 52-Week Low | $17.82 |
| Volume | 14 |
| Avg Volume | 0 |
| Revenue (TTM) | $754.04M |
| Net Income | $73.06M |
| Gross Margin | 89.31% |
7 analysts cover KNSA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $64.00.